Skip to main content
46 search results for:

John Wilding 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. 19-01-2022 | Hyperglycemia | View from the clinic | Article

    Corticosteroid treatment and the consequences for glucose control

    John Wilding highlights the issue of hyperglycemia triggered by use of high-dose steroids and discusses management strategies.

  2. play
    29-06-2021 | ADA 2021 | Conference coverage | Video

    The SURPASS trials so far: Tirzepatide, semaglutide, and type 2 diabetes

    John Wilding gives an overview of the SURPASS findings to date, and discusses their importance and how tirzepatide may be used in the clinic.

  3. 11-02-2021 | Semaglutide | Commentary | Article

    STEP 1: Semaglutide for weight loss

    Lead author of the STEP 1 trial, John Wilding, discusses the findings and what they may mean for the treatment of people with obesity (5:42)

  4. 14-10-2020 | Type 2 diabetes | Editorial | Article

    Tirzepatide: A new challenger for type 2 diabetes management?

    What does the future hold for the novel agent tirzepatide, a GIP/GLP-1 co-agonist? John Wilding examines what we know so far.

  5. 14-12-2018 | Sleep apnea | Editorial | Article

    Diabetes and obstructive sleep apnea syndrome: Double trouble

    Obstructive sleep apnea syndrome is a common and potentially serious comorbidity in people with diabetes and obesity. John Wilding highlights what you need to know about the condition.

  6. 09-05-2022 | Semaglutide | News | Article

    Bodyweight rebounds after semaglutide withdrawal

    John Wilding (University of Liverpool, UK) and co-researchers say this is in line with studies of other weight loss medications, which also showed weight regain after withdrawal.

  7. 06-05-2020 | Type 2 diabetes | Editorial | Article

    Oral semaglutide: A technical triumph, with caveats

    Diabetologist and Editorial Board member John Wilding gives his opinion on the latest addition to the GLP-1RA class, oral semaglutide.

  8. 28-11-2017 | Type 2 diabetes | Editorial | Article

    Real-world evidence: Complementing clinical trials in type 2 diabetes

    Editorial Board member John Wilding examines what real-world data means to today’s clinicians and presents his vision for the future of this type of evidence.

  9. 06-03-2019 | Diet | Video | Article

    Expert commentary: The 2-year DiRECT outcomes

    John Wilding discusses the implications of the 2-year outcomes of the DiRECT trial, and the questions that remain unanswered (4:17).

  10. 12-08-2019 | Metabolic surgery | News | Article

    Bariatric surgery linked to late adverse events

    People who undergo bariatric surgery have a lower long-term risk for mortality, but a higher risk for adverse events such as gastrointestinal and nutritional disorders, compared with those who do not undergo surgery, researchers report. Read the linked commentary from John Wilding

  11. 04-11-2016 | Clinical trial | Editorial | Article

    My EASD 2016 Highlights: From Paleolithic diets to the artificial pancreas

    Editorial board member John Wilding outlines key moments from the 52nd annual meeting of the European Association for the Study of Diabetes in Munich, Germany.

  12. 24-06-2020 | ADA 2020 | Conference coverage | Article

    ADA 2020 goes virtual! Editorial Board conference highlights

    Speakers:   Lori Berard , John Wilding , Sanjay Kalra Owing to the COVID-19 pandemic, the 80th ADA Scientific Sessions was an entirely online event.

  13. 16-04-2019 | Nephropathy | Video | Article

    Diabetes expert commentary: The CREDENCE trial

    In this video interview, diabetes specialist John Wilding discusses how the CREDENCE trial findings may impact the treatment of people with type 2 diabetes and chronic kidney disease (3:31).

  14. 28-11-2018 | SGLT2 inhibitors | Commentary | Article
    Expert commentary

    What can real-world studies really tell us about amputation risk for SGLT2 inhibitors?

    John Wilding considers the real-world studies examining the association between SGLT2 inhibitors and amputation risk in patients with type 2 diabetes.

  15. 07-06-2017 | Metabolic surgery | Hot topic review | Article

    Metabolic surgery: A powerful solution or a last resort?

    medwireNews  rounds up the evidence supporting bariatric surgery as an important treatment option for patients with type 2 diabetes, and asks John Wilding about its place within modern diabetes care.

  16. UK nutrition guidelines: A fresh approach

    Board members John Wilding and Pamela Dyson talk about the fresh approach taken to the latest update of the Diabetes UK nutrition guidelines (9:43).

  17. 16-01-2018 | Type 1 diabetes | Editorial | Article

    Sodium-glucose cotransporter-2 inhibitors for type 1 diabetes: Ready for prime time?

    Editorial board member John Wilding casts a critical eye over the positive buzz surrounding the potential uses of sodium-glucose cotransporter 2 inhibitors in type 1 diabetes treatment.

  18. 03-01-2018 | Physical activity | Editorial | Article

    Physical activity for health, weight loss, and diabetes prevention and treatment: What should be recommended?

    Editorial Board member John Wilding highlights the current evidence for the benefits of physical activity across various domains of type 2 diabetes care and prevention, presenting his view of what should be recommended.

  19. 26-07-2017 | Metabolic surgery | Editorial | Article

    Why don’t we offer bariatric surgery to more people with diabetes in the UK?

    Editorial Board member John Wilding discusses the place of bariatric surgery in the treatment of type 2 diabetes and whether we should be offering more people surgery as a treatment option in the UK.

  20. 24-09-2019 | Type 2 diabetes | Podcast | Article

    How was it for you? The experts discuss EASD 2019

    Listen to diabetologist John Wilding, nurse educator Lori Berard, and primary care specialist Amrit Lamba discussing their EASD 2019 highlights, which include new treatment options for children and older adults with type 2 diabetes, the complexities surrounding hypoglycemia prevention, and the implications of the VERIFY trial (22:07).

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.